Chiang AC, Massagué J (2008) Molecular basis of metastasis. N Engl J Med 359:2814–2823

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60–72

Article  CAS  PubMed  Google Scholar 

Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

Article  CAS  PubMed  Google Scholar 

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

Article  CAS  PubMed  PubMed Central  Google Scholar 

Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3(2):65–71

CAS  PubMed  Google Scholar 

Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932

Article  PubMed  Google Scholar 

Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Pérez-Ruixo JJ (2012) Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 51:247–260

Article  CAS  PubMed  Google Scholar 

Hallmer F, Andersson G, Götrick B, Warfvinge G, Anderud J, Bjørnland T (2018) Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw—a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126:477–485

Article  PubMed  Google Scholar 

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132

Article  CAS  PubMed  Google Scholar 

Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18:2015–2019

Article  CAS  PubMed  Google Scholar 

Jeong H-G, Hwang JJ, Lee J-H, Kim YH, Na JY, Han S-S (2017) Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates. Imaging Sci Dent 47:45

Article  PubMed  PubMed Central  Google Scholar 

Korea Ministry of Food and Drug Safety. Drug details: Prolia. Korea Ministry of Food and Drug Safety. Available online at https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=201404452aupdateTs2024-10-05%2011:05:49.0b

Korea Ministry of Food and Drug Safety. Drug details: Xgeva. Korea Ministry of Food and Drug Safety. Available online at https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=201404453aupdateTs2024-10-05%2011:10:54.0b

Korea National Cancer Information Center. 5-year relative survival rate trends for major cancer. Korea National Cancer Information Center. Available online at https://www.cancer.go.kr/lay1/S1T648C652/contents.do

Kwoen MJ, Park JH, Kim KS, Lee JR, Kim JW, Lee H, Lee HJ (2023) Association between periodontal disease, tooth extraction, and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: a national cohort-based study. J Periodontol 94:98–107

Article  CAS  PubMed  Google Scholar 

Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S (2008) Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634–4638

Article  PubMed  Google Scholar 

Lorenzo-Pouso AI, Pérez-Sayáns M, Chamorro-Petronacci C, Gándara-Vila P, López-Jornet P, Carballo J, García-García A (2020) Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Oral Pathol Med 49:190–200

Article  PubMed  Google Scholar 

O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A (2017) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003474.pub4

Article  PubMed  PubMed Central  Google Scholar 

Ribatti D, Mangialardi G, Vacca A (2006) Stephen Paget and the ‘seed and soil’theory of metastatic dissemination. Clin Exp Med 6:145–149

Article  CAS  PubMed  Google Scholar 

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the Jaws—2022 update. J Oral Maxillofac Surg 80:920–943

Article  PubMed  Google Scholar 

Saad F, Brown J, Van Poznak C, Ibrahim T, Stemmer S, Stopeck A, Diel I, Takahashi S, Shore N, Henry D (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347

Article  CAS  PubMed  Google Scholar 

Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G (2014) The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol 78:477–487

Article  CAS  PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. Prolia (denosumab) Label. U.S. Food and Drug Administration. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s216lbl.pdf

U.S. Food and Drug Administration. Xgeva (denosumab) Label. U.S. Food and Drug Administration. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125320s094lbl.pdf

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362

Article  CAS  PubMed  Google Scholar 

Verron E, Schmid-Antomarchi H, Pascal-Mousselard H, Schmid-Alliana A, Scimeca J-C, Bouler J-M (2014) Therapeutic strategies for treating osteolytic bone metastases. Drug Discovery Today 19:1419–1426

Article  CAS  PubMed  Google Scholar 

Zaheer S, LeBoff M, Lewiecki EM (2015) Denosumab for the treatment of osteoporosis. Exp Opin Drug Metab Toxicol 11:461–470

Article  CAS  Google Scholar